Brachytherapy · 2026
Pelvic chemoradiation with high-dose-rate brachytherapy boost for synchronous prostate and rectal cancers: A rare case series and treatment framework.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Saini Aren Singh, Kumar Ritesh, Bustillos Isabella, Garg Aditya, Peterson John, Portelance Lorraine, Tharp Morgan, Yamoah Kosj, Grass G Daniel, Frakes Jessica M, Hoffe Sarah E, Hunt Dylan C, Saini Amarjit S, Fernandez Daniel C, Ennis Ronald D, Rishi Anupam
Аннотация
PURPOSE: Synchronous prostate and rectal cancers pose therapeutic challenges. Prostate external beam radiation therapy may increase rectal dose and impair anastomotic healing after chemoradiation (CRT). High-dose-rate brachytherapy (HDR-BT) enables prostate dose escalation, minimizing rectal exposure. We report outcomes of pelvic CRT plus HDR-BT boost and propose a treatment algorithm.
METHODS: We retrospectively reviewed a multi-institutional database (2011-2023) to identify patients with synchronous prostate and rectal/anal cancers treated with curative intent. All received pelvic CRT (45-50.4 Gy/25-28 fractions) with concurrent 5-FU or capecitabine ± total neoadjuvant therapy. HDR-BT boosts were delivered to the prostate ± seminal vesicles, meeting objectives of prostate V100 ≥ 95%, rectum V75% < 1 cc, and urethra D10 ≤ 115%. Toxicities were graded per CTCAE v5.0; oncologic outcomes were assessed.
RESULTS: Six men (age 60-78) completed CRT, HDR-BT, and surgery/nonoperative management without interruptions. At median 40 months (range 30-110) follow-up post-BT, no locoregional failures occurred; two rectal cancers achieved pathologic complete response, and four remained recurrence-free. All prostate cancers were biochemically controlled; two rectal cancers developed distant metastasis at ∼2-3 years. HDR-BT achieved excellent prostate coverage (V100 94.6%-97.7%, D90 103%-108%) and rectal sparing (D2cc 40%-72% of prescription, V75 ≤ 1.4 cc). One late grade 3 proctitis/urethral stricture occurred in a fractionated high-dose case; none ≥ grade 3 GU/GI in the single-fraction cohort.
CONCLUSION: CRT followed by HDR-BT prostate boost is feasible, maintains anastomotic safety, and achieves excellent local control and dosimetry with minimal severe toxicity.
METHODS: We retrospectively reviewed a multi-institutional database (2011-2023) to identify patients with synchronous prostate and rectal/anal cancers treated with curative intent. All received pelvic CRT (45-50.4 Gy/25-28 fractions) with concurrent 5-FU or capecitabine ± total neoadjuvant therapy. HDR-BT boosts were delivered to the prostate ± seminal vesicles, meeting objectives of prostate V100 ≥ 95%, rectum V75% < 1 cc, and urethra D10 ≤ 115%. Toxicities were graded per CTCAE v5.0; oncologic outcomes were assessed.
RESULTS: Six men (age 60-78) completed CRT, HDR-BT, and surgery/nonoperative management without interruptions. At median 40 months (range 30-110) follow-up post-BT, no locoregional failures occurred; two rectal cancers achieved pathologic complete response, and four remained recurrence-free. All prostate cancers were biochemically controlled; two rectal cancers developed distant metastasis at ∼2-3 years. HDR-BT achieved excellent prostate coverage (V100 94.6%-97.7%, D90 103%-108%) and rectal sparing (D2cc 40%-72% of prescription, V75 ≤ 1.4 cc). One late grade 3 proctitis/urethral stricture occurred in a fractionated high-dose case; none ≥ grade 3 GU/GI in the single-fraction cohort.
CONCLUSION: CRT followed by HDR-BT prostate boost is feasible, maintains anastomotic safety, and achieves excellent local control and dosimetry with minimal severe toxicity.